EchoIQ Limited (AU:EIQ) has released an update.
EchoIQ Limited has achieved a breakthrough in heart failure detection, with their AI system accurately identifying 86% of cases, far surpassing the standard clinical detection rate of 46%. When combined with clinical evaluations, the accuracy soared to 97% for high-risk patients. These compelling results, presented at the prestigious ESC Congress 2024, are expected to drive significant commercial interest and support EchoIQ’s FDA application for their AI as a diagnostic aid.
For further insights into AU:EIQ stock, check out TipRanks’ Stock Analysis page.
